/

PACB

Pacific Biosciences of CalifornOpen

2.09−0.01 −0.26%USD

NasdaqGS · as of Oct 13, 12:40 ET · 15m delay

Open

2.07

Prev close

2.10

Day range

1.992.14

52-week range

1.073.44

Volume

5.61M0.53×

Mkt cap

651.04M

P/E ttm

—

Fwd P/E

-4.97

EPS ttm

-0.4300

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−39.11%

Price Chart

Yahoo Finance · delayed

PACBOct 13, 2026O 2.07H 2.14L 1.99C 2.09−0.01 (−0.26%)Vol 5.61M

SMA 501.57
SMA 2001.59

1Y change +47.50% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PACB Pacific Biosciences of Californ · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −22.43%
1 month: +61.12%
3 months: +39.63%
6 months: +33.41%
Year to date: +12.01%
1 year: +29.29%

Valuation & ownership

Market cap: 651.19M
Enterprise value: 1.12B
P/E (ttm): —
Forward P/E: -4.97
PEG ratio: —
Price / book: —
Price / sales (ttm): 4.09
EV / EBITDA: 5.65
EPS (ttm): -0.4300
EPS (forward): -0.4214
Beta (5y monthly): 2.19
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 310.83M
Float: 304.17M
Short % of float: 17.46%
Short ratio (days): 4.51
Held by insiders: 8.86%
Held by institutions: 55.44%
Avg volume (3m): 10.59M
50-day average: 1.55
200-day average: 1.59
52-week change: +29.29%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 54.4
vs 50-day SMA: +33.59%
vs 200-day SMA: +31.38%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.10%
Realised vol (20d, ann.): 140.1%
From 52-week high: −39.11%
From 52-week low: +95.75%

ANR

Analyst Consensus

7 analysts

Consensus

Buy

2.13 on a 1 (strong buy) – 5 (sell) scale

Mean target

2.40

+14.59% implied

Low 1.25Median 3.00High 3.05

Recommendation trend

Now4 / 3 / 1
1m ago4 / 3 / 1

DES

About Pacific Biosciences of Californ

Yahoo Finance profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Sector: Healthcare
Industry: Medical Devices
Employees: 485
Headquarters: Menlo Park, CA, United States
Website

SEAS

Seasonality · PACB

2010–2026 · monthly returns

Strongest month Oct +14.19%Weakest month Apr −9.66%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	20.9	-25.7	-21.4	20.5	-6.3	12.8	-16.7	-2.9	74.3	-11.6			+12.0%
2025	-15.8	-5.8	-18.6	-5.9	-13.5	29.2	11.3	-5.1	-2.3	82.8	-0.9	-19.4	+2.2%
2024	-33.6	-15.1	-32.2	-56.0	8.5	-23.5	50.4	-33.5	24.1	27.6	-12.0	-4.2	−81.3%
2023	35.6	-18.1	27.5	-8.5	16.8	7.4	-0.7	-14.6	-26.0	-26.0	37.2	15.7	+19.9%
2022	-45.4	6.6	-23.7	-30.3	-11.2	-21.5	-1.1	34.1	-0.9	45.3	27.4	-23.9	−60.0%
2021	24.7	-5.5	9.0	-10.4	-9.4	29.3	-8.1	-2.6	-18.4	3.6	-12.3	-11.8	−21.1%
2020	-9.1	-27.2	-10.0	8.2	6.3	-2.0	8.1	76.9	49.5	32.8	20.6	64.1	+404.7%
2019	-6.5	5.6	-1.1	2.2	-9.3	-9.7	-10.7	2.8	-7.0	-6.2	6.2	0.0	−30.5%
2018	7.6	-16.2	-13.9	25.9	-1.9	40.3	7.0	31.3	8.4	-17.7	75.7	-5.4	+180.3%
2017	26.8	4.8	2.4	-23.8	-16.2	7.9	-8.4	51.8	6.1	-19.4	-24.6	-17.2	−30.5%
2016	-18.6	-22.5	2.5	13.5	-0.1	-27.0	21.4	-2.6	7.6	-5.1	-10.5	-50.1	−71.1%
2015	2.6	-21.6	-7.3	-11.6	9.3	2.1	-1.2	-12.5	-26.5	94.0	44.1	28.3	+67.5%
2014	37.3	-7.2	-19.7	-17.4	12.2	24.6	-26.1	28.2	-16.2	33.6	3.0	16.0	+49.9%
2013	45.9	-7.3	8.3	2.8	3.5	-4.5	2.4	61.4	32.1	-25.5	2.7	23.9	+207.6%
2012	60.0	-6.9	-18.0	-21.1	-12.6	-8.1	-16.6	8.8	-7.1	-29.0	29.2	1.2	−39.3%
2011	-0.7	-0.4	-10.7	-12.5	-2.7	-2.3	-5.9	-35.7	-54.7	22.1	-27.3	-1.8	−82.4%
2010											-25.0	26.3	−5.3%

INSD

Insider Activity · PACB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

989.1K shares

Sells, 6 months

688.7K shares

Net shares

+300.4K

Net change in insider shares

+1.10%

Date	Insider	Transaction	Shares	Value
Oct 5, 2026	Gibson James R IiChief Financial Officer	Sale at price 3.11 per share.	661.8K	$2.06M
Oct 5, 2026	Gibson James R IiChief Financial Officer	Conversion of Exercise of derivative security at price 1.18 per share.	500K	$590.00K
Aug 16, 2026	Van Oene Mark DChief Executive Officer	Sale at price 1.13 per share.	26.9K	$30.41K
Aug 9, 2026	Van Oene Mark DChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	489.1K	—
Apr 7, 2026	Gibson Christopher C.Director	Stock Award(Grant) at price 0.00 per share.	57.5K	—
Mar 31, 2026	Gibson James R IiChief Financial Officer	Sale at price 1.37 per share.	88.2K	$120.81K
Mar 2, 2026	Gibson Christopher C.Director	Stock Award(Grant) at price 0.00 per share.	53.9K	—
Mar 2, 2026	Van Oene Mark DChief Operating Officer	Sale at price 1.51 per share.	6.5K	$9.85K
Mar 2, 2026	Farmer Michele CpaOfficer	Sale at price 1.51 per share.	3K	$4.51K
Mar 2, 2026	Henry Christian OChief Executive Officer	Sale at price 1.51 per share.	12.5K	$18.92K
Feb 26, 2026	Van Oene Mark DChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	500K	—
Feb 26, 2026	Farmer Michele CpaOfficer	Stock Award(Grant) at price 0.00 per share.	89.8K	—
Feb 26, 2026	Henry Christian OChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	920.8K	—
Feb 26, 2026	Gibson James R IiChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	333.8K	—
Feb 17, 2026	Van Oene Mark DChief Operating Officer	Sale at price 1.58 - 1.63 per share.	184.9K	$294.32K
Feb 17, 2026	Farmer Michele CpaOfficer	Sale at price 1.58 - 1.63 per share.	50.2K	$79.86K
Feb 17, 2026	Henry Christian OChief Executive Officer	Sale at price 1.58 - 1.63 per share.	472.7K	$752.39K
Aug 17, 2025	Van Oene Mark DChief Operating Officer	Sale at price 1.31 per share.	26.8K	$35.18K
May 18, 2025	Farmer Michele CpaOfficer	Sale at price 1.00 per share.	5.2K	$5.20K
Mar 30, 2025	Gibson James R IiChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	1.00M	—

13F

Investors Holding PACB

latest 13F filings of 29 followed managers

Investors holding PACB
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$50.0M	0.32%	29.78M	−18%	Q2 2026
Renaissance Technologies	$1.6M	0.00%	966.20K	−61%	Q2 2026
Bridgewater Associates · Ray Dalio	$172.6K	0.00%	102.76K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PACB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PACB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pacific Biosciences of Californ

Seasonality · PACB

Insider Activity · PACB

Congress Trades · PACB

Investors Holding PACB

Investors Holding PACB

Congress Trades · PACB

Insider Activity · PACB

Seasonality · PACB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pacific Biosciences of Californ

Financial Snapshot

Earnings & Dividends

News